New options and new questions: how to select and sequence therapies for patients with metastatic melanoma.
Recent advances in the understanding of the melanoma biology and tumor immunology have yielded new treatment strategies for patients with advanced melanoma. Within the past year, the selective BRAF inhibitor vemurafenib and immune checkpoint inhibitor ipilimumab have been added to the treatment armamentarium. In addition, other molecularly targeted agents and immunotherapies are showing considerable promise. The availability of multiple, effective treatment options for patients with melanoma, although long sought, has complicated treatment decisions. This article will review the advances in our understanding of melanoma biology and tumor immunology, the current status of immunotherapy, the advances in molecularly targeted therapy for patients with BRAF mutant melanomas, the possible approaches to patients with BRAF wild-type (WT) tumors, and the current considerations for treatment selection of individual patients.
From the Massachusetts General Hospital Cancer Center, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; Beth Israel Deaconess Medical Center, Boston, MA.
Keith T
KT
Flaherty
From the Massachusetts General Hospital Cancer Center, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; Beth Israel Deaconess Medical Center, Boston, MA.
Jeff A
JA
Sosman
From the Massachusetts General Hospital Cancer Center, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; Beth Israel Deaconess Medical Center, Boston, MA.
Michael B
MB
Atkins